Analysis of 307 cases with drug‐induced liver injury between 2010 and 2018 in Japan
Hepatology Research2018Vol. 49(1), pp. 105–110
Citations Over TimeTop 10% of 2018 papers
Mitsuhiko Aiso, Hajime Takikawa, Keiji Tsuji, Tatehiro Kagawa, Masaaki Watanabe, Atsushi Tanaka, Ken Sato, Shotaro Sakisaka, Yoichi Hiasa, Yoshiyuki Takei, Hiromasa Ohira, Minoru Ayada, Etsuko Hashimoto, Shuichi Kaneko, Yoshiyuki Ueno, Kenji Ohmoto, Akinobu Takaki, Takuji Torimura, Yasushi Matsuzaki, Kazuto Tajiri, Masashi Yoneda, Takayoshi Ito, Naoya Kato, Kenichi Ikejima, Satoshi Mochida, Hiroshi Yasuda, Naoya Sakamoto
Abstract
Japanese DILI patients are somewhat different from those of Europe and North America. The diagnostic scale of the DDW-Japan 2004 workshop has been used in Japan. However, there are many issues to improve the causality assessment of DILI that we must investigate in the future. It is critical to elucidate the mechanisms of drug metabolism and the pathophysiology of liver injury by various drugs to prevent DILI.
Related Papers
- → Drug-Induced Liver Disease(2012)93 cited
- Drug-induced liver injuries: Drug-induced liver injury is a significant cause of liver disease, including chronic liver disease(2011)
- Drug-induced liver injuries : main article(2011)
- Drug-induced liver disease(2008)
- Drug-induced liver disease : main article(2005)